SCHEMBL6507516

SCHEMBL6507516

NC(=O)Nc1cn(-c2cc(-c3ccccc3)ccc2N)nc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.48
IKBKB O14920 3/20 0.45
HDAC2 Q92769 10/20 0.44
HDAC1 Q13547 8/20 0.44
HDAC3 O15379 5/20 0.44
IRAK4 Q9NWZ3 1/20 0.41
MAP2K3 P46734 1/20 0.40
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499042 0.83 KDM4E (0.49) ITKIKBKBIRAK4KDM4ENPC1
SCHEMBL6497388 0.82 KDM4E (0.53) ITKIKBKBIRAK4KDM4ENPC1
SCHEMBL6501255 0.80 ITK (0.45) ITKIKBKBHDAC1IRAK4KDM4E
SCHEMBL6500705 0.78 MEN1 (0.44) ITKIRAK4KDM4ENPC1ALDH1A1
SCHEMBL6472225 0.78 KMO (0.46) ITKIRAK4KDM4ENPC1ALDH1A1
SCHEMBL6500784 0.78 HDAC1 (0.44) ITKHDAC2HDAC1HDAC3KDM4E
SCHEMBL6498765 0.78 MAPT (0.46) ITKIKBKBIRAK4KDM4ENPC1
SCHEMBL6499548 0.78 ITK (0.45) ITKIKBKBIRAK4KDM4ENPC1
SCHEMBL6508388 0.77 ITK (0.47) ITKHDAC2IRAK4KDM4ENPC1
SCHEMBL6501596 0.77 IKBKB (0.47) ITKIKBKBIRAK4KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
WO-2005003140-A1 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 ITK 4236/4885IKBKB 664/4885HDAC2 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.